29/05/2024
As part of the bipartisan bill to modernize radiation oncology reimbursement introduced in the U.S. Congress, The Radiation Oncology Case Rate (ROCR) Value-Based Payment Program Act would improve access, enhance quality and support shorter treatments for certain cancers. This would allow patients to return to work faster and spend more time with loved ones while undergoing the treatment process. Read full statement here: https://lnkd.in/e3qCH2t6
Xcision Medical Systems fully supports policymakers and radiation oncology stakeholders that are part of this pioneering program to enhance the landscape of cancer treatment across the United States.
Michelle Crawley, President of Xcision, commented on how the ROCR’s ability to maximize care and minimize costs for providers and patients fits perfectly with Xcision’s GammaPod radiotherapy system, noting that:
👍GammaPod provides highly conformal, non-invasive early-stage breast cancer treatments that can shorten the course of radiotherapy, while limiting doses to the whole breast, heart and lungs.
👍GammaPod addresses the growing global demand for high-value radiation therapy, more efficient and cost-effective breast cancer care by helping patients with early-stage breast cancer get back to their lives faster.
To learn more about how GammaPod is a smart choice for cancer care providers, visit https://xcision.com/.
hashtag
